Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease

Review of the clinical literature

Charles P. Semba, Timothy P. Murphy, Curtis W. Bakal, Karim A. Calis, Terence A S Matalon, Paramjit Chopra, Patricia E. Cole, Anthony J. Comerota, Buddy Connors, Jacob Cynamon, Gerald E. Grubbs, Ziv Haskal, Suzanne La Vere Herbst, David W. Hunter, Kathy Phelps, David Stump, Steven Thomas, David L. Warner, Gerald Zemel

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

PURPOSE: The clinical literature describing the use of alteplase in the treatment of peripheral arterial occlusive (PAO) disease is reviewed. MATERIALS AND METHODS: The literature database was acquired by a MEDLINE search using the Boolean keyword string: tissue plasminogen activator and/or rt-PA and peripheral not animal. A review was performed to identify the dose range of alteplase, technique of infusion, use of anticoagulation, clinical success rates, and risk of complications. RESULTS: Forty-six clinical studies were identified. There are few prospective, randomized clinical trials and a lack of standardized protocols and endpoints. Use of catheter-directed infusions of recombinant tissue plasminogen activator (rt-PA) may be beneficial versus surgery in the initial management of acute limb ischemia (< 14 days) and in reducing the magnitude of subsequent surgical or percutaneous revascularization. For patients with chronic limb ischemia (> 14 days), irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheter-directed infusion of rt-PA or other plasminogen activators may be unsuitable. The risk of adverse bleeding appears related to the overall dose and duration of infusion. These risks appear similar to those of urokinase. The role of heparin in increasing adverse bleeding during rt-PA therapy is unclear. CONCLUSIONS: There is no generally accepted dose or technique for administering catheter-directed thrombolysis using alteplase; however, several studies have demonstrated its clinical safety and efficacy. Formal studies will be required to determine the optimal dose, technique of infusion, the role of anticoagulation, and complication rates when alteplase is used for PAO disease.

Original languageEnglish (US)
Pages (from-to)149-161
Number of pages13
JournalJournal of Vascular and Interventional Radiology
Volume11
Issue number2 I
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Arterial Occlusive Diseases
Peripheral Arterial Disease
Thrombolytic Therapy
Tissue Plasminogen Activator
Catheters
Ischemia
Extremities
Hemorrhage
Plasminogen Activators
Urokinase-Type Plasminogen Activator
MEDLINE
Heparin
Randomized Controlled Trials
Databases
Safety

Keywords

  • Alteplase
  • Arteries, peripheral
  • Arteries, stenosis or obstruction
  • Thrombolysis
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Semba, C. P., Murphy, T. P., Bakal, C. W., Calis, K. A., Matalon, T. A. S., Chopra, P., ... Zemel, G. (2000). Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature. Journal of Vascular and Interventional Radiology, 11(2 I), 149-161.

Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease : Review of the clinical literature. / Semba, Charles P.; Murphy, Timothy P.; Bakal, Curtis W.; Calis, Karim A.; Matalon, Terence A S; Chopra, Paramjit; Cole, Patricia E.; Comerota, Anthony J.; Connors, Buddy; Cynamon, Jacob; Grubbs, Gerald E.; Haskal, Ziv; Herbst, Suzanne La Vere; Hunter, David W.; Phelps, Kathy; Stump, David; Thomas, Steven; Warner, David L.; Zemel, Gerald.

In: Journal of Vascular and Interventional Radiology, Vol. 11, No. 2 I, 02.2000, p. 149-161.

Research output: Contribution to journalArticle

Semba, CP, Murphy, TP, Bakal, CW, Calis, KA, Matalon, TAS, Chopra, P, Cole, PE, Comerota, AJ, Connors, B, Cynamon, J, Grubbs, GE, Haskal, Z, Herbst, SLV, Hunter, DW, Phelps, K, Stump, D, Thomas, S, Warner, DL & Zemel, G 2000, 'Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature', Journal of Vascular and Interventional Radiology, vol. 11, no. 2 I, pp. 149-161.
Semba, Charles P. ; Murphy, Timothy P. ; Bakal, Curtis W. ; Calis, Karim A. ; Matalon, Terence A S ; Chopra, Paramjit ; Cole, Patricia E. ; Comerota, Anthony J. ; Connors, Buddy ; Cynamon, Jacob ; Grubbs, Gerald E. ; Haskal, Ziv ; Herbst, Suzanne La Vere ; Hunter, David W. ; Phelps, Kathy ; Stump, David ; Thomas, Steven ; Warner, David L. ; Zemel, Gerald. / Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease : Review of the clinical literature. In: Journal of Vascular and Interventional Radiology. 2000 ; Vol. 11, No. 2 I. pp. 149-161.
@article{e6028c210b76448395aacdb52aa19bdf,
title = "Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature",
abstract = "PURPOSE: The clinical literature describing the use of alteplase in the treatment of peripheral arterial occlusive (PAO) disease is reviewed. MATERIALS AND METHODS: The literature database was acquired by a MEDLINE search using the Boolean keyword string: tissue plasminogen activator and/or rt-PA and peripheral not animal. A review was performed to identify the dose range of alteplase, technique of infusion, use of anticoagulation, clinical success rates, and risk of complications. RESULTS: Forty-six clinical studies were identified. There are few prospective, randomized clinical trials and a lack of standardized protocols and endpoints. Use of catheter-directed infusions of recombinant tissue plasminogen activator (rt-PA) may be beneficial versus surgery in the initial management of acute limb ischemia (< 14 days) and in reducing the magnitude of subsequent surgical or percutaneous revascularization. For patients with chronic limb ischemia (> 14 days), irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheter-directed infusion of rt-PA or other plasminogen activators may be unsuitable. The risk of adverse bleeding appears related to the overall dose and duration of infusion. These risks appear similar to those of urokinase. The role of heparin in increasing adverse bleeding during rt-PA therapy is unclear. CONCLUSIONS: There is no generally accepted dose or technique for administering catheter-directed thrombolysis using alteplase; however, several studies have demonstrated its clinical safety and efficacy. Formal studies will be required to determine the optimal dose, technique of infusion, the role of anticoagulation, and complication rates when alteplase is used for PAO disease.",
keywords = "Alteplase, Arteries, peripheral, Arteries, stenosis or obstruction, Thrombolysis, Tissue plasminogen activator",
author = "Semba, {Charles P.} and Murphy, {Timothy P.} and Bakal, {Curtis W.} and Calis, {Karim A.} and Matalon, {Terence A S} and Paramjit Chopra and Cole, {Patricia E.} and Comerota, {Anthony J.} and Buddy Connors and Jacob Cynamon and Grubbs, {Gerald E.} and Ziv Haskal and Herbst, {Suzanne La Vere} and Hunter, {David W.} and Kathy Phelps and David Stump and Steven Thomas and Warner, {David L.} and Gerald Zemel",
year = "2000",
month = "2",
language = "English (US)",
volume = "11",
pages = "149--161",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "2 I",

}

TY - JOUR

T1 - Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease

T2 - Review of the clinical literature

AU - Semba, Charles P.

AU - Murphy, Timothy P.

AU - Bakal, Curtis W.

AU - Calis, Karim A.

AU - Matalon, Terence A S

AU - Chopra, Paramjit

AU - Cole, Patricia E.

AU - Comerota, Anthony J.

AU - Connors, Buddy

AU - Cynamon, Jacob

AU - Grubbs, Gerald E.

AU - Haskal, Ziv

AU - Herbst, Suzanne La Vere

AU - Hunter, David W.

AU - Phelps, Kathy

AU - Stump, David

AU - Thomas, Steven

AU - Warner, David L.

AU - Zemel, Gerald

PY - 2000/2

Y1 - 2000/2

N2 - PURPOSE: The clinical literature describing the use of alteplase in the treatment of peripheral arterial occlusive (PAO) disease is reviewed. MATERIALS AND METHODS: The literature database was acquired by a MEDLINE search using the Boolean keyword string: tissue plasminogen activator and/or rt-PA and peripheral not animal. A review was performed to identify the dose range of alteplase, technique of infusion, use of anticoagulation, clinical success rates, and risk of complications. RESULTS: Forty-six clinical studies were identified. There are few prospective, randomized clinical trials and a lack of standardized protocols and endpoints. Use of catheter-directed infusions of recombinant tissue plasminogen activator (rt-PA) may be beneficial versus surgery in the initial management of acute limb ischemia (< 14 days) and in reducing the magnitude of subsequent surgical or percutaneous revascularization. For patients with chronic limb ischemia (> 14 days), irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheter-directed infusion of rt-PA or other plasminogen activators may be unsuitable. The risk of adverse bleeding appears related to the overall dose and duration of infusion. These risks appear similar to those of urokinase. The role of heparin in increasing adverse bleeding during rt-PA therapy is unclear. CONCLUSIONS: There is no generally accepted dose or technique for administering catheter-directed thrombolysis using alteplase; however, several studies have demonstrated its clinical safety and efficacy. Formal studies will be required to determine the optimal dose, technique of infusion, the role of anticoagulation, and complication rates when alteplase is used for PAO disease.

AB - PURPOSE: The clinical literature describing the use of alteplase in the treatment of peripheral arterial occlusive (PAO) disease is reviewed. MATERIALS AND METHODS: The literature database was acquired by a MEDLINE search using the Boolean keyword string: tissue plasminogen activator and/or rt-PA and peripheral not animal. A review was performed to identify the dose range of alteplase, technique of infusion, use of anticoagulation, clinical success rates, and risk of complications. RESULTS: Forty-six clinical studies were identified. There are few prospective, randomized clinical trials and a lack of standardized protocols and endpoints. Use of catheter-directed infusions of recombinant tissue plasminogen activator (rt-PA) may be beneficial versus surgery in the initial management of acute limb ischemia (< 14 days) and in reducing the magnitude of subsequent surgical or percutaneous revascularization. For patients with chronic limb ischemia (> 14 days), irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheter-directed infusion of rt-PA or other plasminogen activators may be unsuitable. The risk of adverse bleeding appears related to the overall dose and duration of infusion. These risks appear similar to those of urokinase. The role of heparin in increasing adverse bleeding during rt-PA therapy is unclear. CONCLUSIONS: There is no generally accepted dose or technique for administering catheter-directed thrombolysis using alteplase; however, several studies have demonstrated its clinical safety and efficacy. Formal studies will be required to determine the optimal dose, technique of infusion, the role of anticoagulation, and complication rates when alteplase is used for PAO disease.

KW - Alteplase

KW - Arteries, peripheral

KW - Arteries, stenosis or obstruction

KW - Thrombolysis

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=0034001707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034001707&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 149

EP - 161

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 2 I

ER -